|
US7608640B2
(en)
|
1999-03-02 |
2009-10-27 |
Jallal Messadek |
Glycine betaine and its use
|
|
JP2005501097A
(ja)
*
|
2001-08-16 |
2005-01-13 |
ザ ステイト オブ オレゴン アクティング バイ アンド スルー ザ ステイト ボード オブ ハイアー エデュケイション、 オン ビハーフ オブ オレゴン ステイト ユニバーシティー |
膨張可能な胃内滞留装置
|
|
BE1015608A6
(fr)
|
2003-07-15 |
2005-06-07 |
Messadek Jallal |
Traitement des arterites.
|
|
US7094427B2
(en)
*
|
2002-05-29 |
2006-08-22 |
Impax Laboratories, Inc. |
Combination immediate release controlled release levodopa/carbidopa dosage forms
|
|
US20030224045A1
(en)
*
|
2002-05-29 |
2003-12-04 |
Chien-Hsuan Han |
Combination immediate release sustained release levodopa/carbidopa dosage forms
|
|
EP1615632B1
(fr)
*
|
2003-04-17 |
2006-12-06 |
Jallal Messadek |
Formulations orales flottantes pour la liberation controlee de la betaine
|
|
JP2007509146A
(ja)
*
|
2003-10-20 |
2007-04-12 |
テバ ファーマシューティカル インダストリーズ リミティド |
レボドーパの持続効果のための組成物及び投与形
|
|
JP2005132803A
(ja)
*
|
2003-10-31 |
2005-05-26 |
Ono Pharmaceut Co Ltd |
胃内滞留固形剤
|
|
TW200533391A
(en)
|
2004-03-25 |
2005-10-16 |
Sun Pharmaceutical Ind Ltd |
Gastric retention drug delivery system
|
|
FR2874325B1
(fr)
*
|
2004-08-19 |
2006-10-20 |
Sanofi Synthelabo |
Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
|
|
WO2006050581A2
(en)
|
2004-11-10 |
2006-05-18 |
Jallal Messadek |
Betaine as agent against arthropod - or mosquito -borne diseases
|
|
EP2242489A1
(en)
|
2005-02-15 |
2010-10-27 |
Jallal Messadek |
Combination therapeutic compositions and method of use
|
|
RU2007143510A
(ru)
|
2005-04-27 |
2009-06-10 |
Яллал МЕССАДЕК (BE) |
Инсулиновые композиции
|
|
NL2000281C2
(nl)
|
2005-11-02 |
2007-08-07 |
Pfizer Prod Inc |
Vaste farmaceutische samenstellingen die pregabaline bevatten.
|
|
KR20090057349A
(ko)
*
|
2006-05-31 |
2009-06-05 |
솔베이 파머슈티컬스 게엠베하 |
레보도파／칼비도파의 ２４시간의 장기간 장내투여
|
|
EP1872775A1
(en)
*
|
2006-06-29 |
2008-01-02 |
Polichem S.A. |
Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders
|
|
PE20080669A1
(es)
*
|
2006-09-08 |
2008-07-18 |
Drugtech Corp |
Composicion de liberacion sostenida que comprende levodopa
|
|
WO2008039186A2
(en)
*
|
2006-09-26 |
2008-04-03 |
Plensat, Llc |
Method and system for treatment of eating disorders
|
|
JPWO2008087882A1
(ja)
|
2007-01-15 |
2010-05-06 |
キッセイ薬品工業株式会社 |
胃内滞留型レボドパ徐放性製剤
|
|
KR20080076382A
(ko)
*
|
2007-02-15 |
2008-08-20 |
(주)아모레퍼시픽 |
실로스타졸의 제어방출 제제 및 그 제조방법
|
|
DE102007026037A1
(de)
*
|
2007-06-04 |
2008-12-11 |
Lts Lohmann Therapie-Systeme Ag |
Gastroretentives System mit Alginat-Körper
|
|
MX2010001071A
(es)
*
|
2007-07-27 |
2010-03-09 |
Depomed Inc |
Formas de dosificacion retentivas gastricas pulsatiles.
|
|
EP2306823A4
(en)
|
2008-06-30 |
2012-09-26 |
Tocagen Inc |
5-FLUOROCYTOSINE FORMULATIONS AND USES THEREOF
|
|
ES2740360T3
(es)
*
|
2008-08-15 |
2020-02-05 |
Assertio Therapeutics Inc |
Composiciones farmacéuticas de retención gástrica para el tratamiento y la prevención de trastornos del SNC
|
|
JP2012508228A
(ja)
*
|
2008-11-07 |
2012-04-05 |
サムヤン コーポレイション |
メチルフェニデートの放出制御用薬剤学的組成物
|
|
EP2661262B1
(en)
*
|
2011-01-06 |
2017-11-15 |
Mahmut Bilgic |
Improved bisphosphonate formulations
|
|
CN103385871B
(zh)
*
|
2012-05-07 |
2017-06-23 |
新疆医科大学 |
复方左旋多巴微囊漂浮片
|
|
US10507127B2
(en)
|
2012-06-07 |
2019-12-17 |
Epitomee Medical Ltd. |
Expandable device
|
|
WO2014174388A1
(en)
*
|
2013-03-29 |
2014-10-30 |
Wockhardt Limited |
Modified release pharmaceutical compositions of methylphenidate or salts thereof
|
|
JP6204141B2
(ja)
*
|
2013-04-22 |
2017-09-27 |
テイカ製薬株式会社 |
口腔内速崩壊性固形製剤用組成物
|
|
WO2014176389A1
(en)
*
|
2013-04-24 |
2014-10-30 |
Temple University - Of The Commonwealth System Of Higher Education |
Solid dosage form containing arabinogalactan
|
|
US10987313B2
(en)
|
2013-10-07 |
2021-04-27 |
Impax Laboratories, Llc |
Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
|
|
CN105658211A
(zh)
|
2013-10-07 |
2016-06-08 |
怡百克制药公司 |
左旋多巴和/或左旋多巴的酯的粘膜粘附性、控制释放调配物和其用途
|
|
WO2015083171A1
(en)
*
|
2013-12-05 |
2015-06-11 |
Tulip Medical Ltd. |
Retentive devices and systems for in-situ release of pharmaceutical active agents
|
|
EP3261625B1
(en)
*
|
2015-02-27 |
2024-08-14 |
Cingulate Therapeutics LLC |
Tripulse release stimulant formulations
|
|
JP6823539B2
(ja)
*
|
2017-05-26 |
2021-02-03 |
株式会社ファンケル |
胃内滞留性錠剤
|
|
US10588863B2
(en)
|
2017-06-16 |
2020-03-17 |
Kashiv Biosciences, Llc |
Extended release compositions comprising pyridostigmine
|
|
US10987311B2
(en)
|
2017-06-16 |
2021-04-27 |
Kashiv Specialty Pharmaceuticals, Llc |
Extended release compositions comprising pyridostigmine
|
|
WO2018232413A1
(en)
|
2017-06-16 |
2018-12-20 |
Kashiv Pharma Llc |
Gastroretentive dosage forms for sustained drug delivery
|
|
DK3609472T3
(da)
|
2018-06-18 |
2021-04-06 |
Kashiv Specialty Pharmaceuticals Llc |
Forlænget frigivelsessammensætning indeholdende pyridostigmin
|
|
JP7034343B2
(ja)
|
2018-06-27 |
2022-03-11 |
アムニール コンプレックス プロダクツ リサーチ エルエルシー |
自己調節性の浸透性胃保持性薬物送達システム
|
|
JP7044649B2
(ja)
*
|
2018-06-28 |
2022-03-30 |
株式会社ファンケル |
胃内浮遊錠剤
|
|
EP3968980A1
(en)
*
|
2019-05-14 |
2022-03-23 |
Clexio Biosciences Ltd. |
Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
|
|
WO2020264092A1
(en)
*
|
2019-06-26 |
2020-12-30 |
Celista Pharmaceuticals Llc |
Atomoxetine hydrochloride extended release compositions and methods of use
|
|
WO2021176361A1
(en)
|
2020-03-02 |
2021-09-10 |
Craft Health Pte Ltd |
Method of manufacturing oral dosage forms for extended drug release
|
|
PL4125842T3
(pl)
|
2020-04-03 |
2024-10-14 |
Beigene, Ltd. |
Równoczesne podawanie mirdametynibu i lifirafenibu do stosowania w leczeniu nowotworów
|
|
US11986449B2
(en)
|
2020-12-22 |
2024-05-21 |
Amneal Pharmaceuticals Llc |
Levodopa dosing regimen
|
|
US12194150B2
(en)
|
2020-12-22 |
2025-01-14 |
Amneal Pharmaceuticals Llc |
Levodopa dosing regimen
|
|
US11571402B2
(en)
*
|
2021-02-17 |
2023-02-07 |
Springworks Therapeutics, Inc. |
Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
|
|
WO2022195476A1
(en)
|
2021-03-15 |
2022-09-22 |
Clexio Biosciences Ltd. |
Gastroretentive devices for assessment of intragastric conditions
|
|
GB202414411D0
(en)
*
|
2024-10-01 |
2024-11-13 |
King S College London |
Hydrogel
|